Skip to content

Medical emergency? What to do

Alteon research collaborator receives funding for diabetic complications study

3-RXPublished September 19, 20063 min read

Key points

  • Crosslink Breaker, alagebrium will be tested for its ability to reverse kidney damage caused by diabetes, and to reverse the protein excretion which is characteristic of diabetic nephropathy.
  • "In preclinical studies, we have shown that renal damage in diabetes is partly caused by sugar-protein complexes called Advanced Glycation End-products (A.G.E.s), and that treatment with alagebrium, an A.G.E.
  • This will be followed by 24 weeks of double-blind treatment with either placebo or alagebrium in combination with an ACE inhibitor.
  • "Based on the preclinical studies performed by Cooper using alagebrium, we are encouraged that this clinical trial may demonstrate clinical utility in type I diabetics," said Parving.

Alteon, Inc., (ALT) announced that one of its collaborators, Mark Cooper, MD, PhD, professor, the Baker Heart Research Institute, Melbourne, Australia, has been awarded a grant from the Juvenile Diabetes Research Foundation (JDRF) to help fund a multinational phase II clinical study of the effect of Alteon's lead compound alagebrium on renal function in patients with type 1 diabetes and microalbuminuria.

An A.G.E. Crosslink Breaker, alagebrium will be tested for its ability to reverse kidney damage caused by diabetes, and to reverse the protein excretion which is characteristic of diabetic nephropathy.

Diabetes is the leading cause of kidney failure in the United States. When blood sugar increases, as it does in diabetes, it non-enzymatically modifies proteins to form chemical structures known as advanced glycation end-products (A.G.E.s), leading to a loss of flexibility and function in tissues and organs throughout the body, including the kidney. Alagebrium chloride is the first in a new class of compounds developed by Alteon to break the A.G.E. crosslinks, and may therefore be a promising new treatment to prevent the kidney failure caused by diabetes. Cooper has performed many preclinical studies that appear to validate the use of alagebrium in diabetic nephropathy.

"In preclinical studies, we have shown that renal damage in diabetes is partly caused by sugar-protein complexes called Advanced Glycation End-products (A.G.E.s), and that treatment with alagebrium, an A.G.E. Crosslink Breaker, can improve renal function and structure," said Cooper. "We are grateful to the JDRF for this grant that will enable us to explore these exciting findings in diabetic patients."

A phase II protocol for the clinical study has been developed. The randomized, double-blind, placebo-controlled study will test alagebrium in 80 patients with type 1 diabetes between the ages of 18-65 who are in the early stages of kidney disease. There will be an 8-week single-blind, run-in period during which placebo and an ACE inhibitor, standard background therapy for this patient population, will be administered to all patients.

This will be followed by 24 weeks of double-blind treatment with either placebo or alagebrium in combination with an ACE inhibitor. Changes in albumin excretion rate will be the primary endpoint of the study. The study, which is expected to be initiated in the fourth quarter of 2006, will be conducted at three sites in Australia and one in Denmark. Notable nephrologist Hans-Henrik Parving, MD, professor of Medicine, Chief Physician, Steno Diabetes Center, Gentofte, Denmark, and Faculty of Health Science, University of Aarhus, Denmark, will serve as the investigator in Denmark.

"We are delighted that we will be working with Drs. Cooper and Parving on this phase II evaluation of alagebrium in diabetic kidney disease, a medical condition in great need of new therapies," said Kenneth I. Moch, president and CEO of Alteon. "This study complements our ongoing phase II efforts in diastolic heart failure, another disease that can be a complication of diabetes."

"Based on the preclinical studies performed by Cooper using alagebrium, we are encouraged that this clinical trial may demonstrate clinical utility in type I diabetics," said Parving. "I look forward to participating in this multinational study."

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underPublic Health
Public Health

Parasitic DNA proliferates in aging tissues

The genomes of organisms from humans to corn are replete with "parasitic" strands of DNA that, when not suppressed, copy themselves and spread throughout the genome, potentially affecting health. Earlier this year…

4 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.